期刊
TRENDS IN ENDOCRINOLOGY AND METABOLISM
卷 30, 期 7, 页码 467-478出版社
CELL PRESS
DOI: 10.1016/j.tem.2019.04.006
关键词
-
资金
- Australian National Health and Medical Research Council of Australia (NHMRC) - European Society of Human Reproduction and Embryology
- American Society for Reproductive Medicine
Polycystic ovary syndrome (PCOS) affects 8-13% of women. The Rotterdam diagnostic criteria include polycystic ovarian morphology (PCOM) on ultrasound, but given recognized challenges, serum anti-Mullerian hormone (AMH) is proposed as an alternative. To inform international PCOS guidelines, a systematic review was completed. Key identified gaps include large international studies in well-defined populations across the lifespan, clustering of AMH with PCOS features, relationships to long-term health outcomes, and improved quality, assay standardization, and sample handling, all needed to determine cut offs. Here we identify research priorities to address these gaps and enhance AMH utility in PCOS. Once issues are addressed, AMH levels could replace more costly and less accessible ultrasound in PCOS diagnosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据